We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Experimental Drug Shows Promise for Treating Small-Cell Lung Cancer

By LabMedica International staff writers
Posted on 30 Nov 2009
Cancer researchers have demonstrated that an experimental drug could successfully eliminate tumors caused by small-cell lung cancer (SCLC) in two different mouse models of the disease.

Lung cancer is the most commonly fatal type of cancer, and small-cell lung cancer is perhaps its deadliest form. SCLC usually responds initially to chemotherapy, but rapidly relapses to a resistant form with an overall survival rate of less than 5%.

Previous studies had shown that fibroblast growth factor-2 (FGF-2) induced proliferation and resistance to chemotherapy in SCLC cells. To capitalize on these findings investigators at Imperial College London (United Kingdom) evaluated the performance of the experimental drug PD173074, a protein kinase inhibitor and angiogenesis inhibitor that blocks the FGF-2 receptor, in two different mouse models of human SCLC.

Results published in the November 15, 2009, issue of the journal Cancer Research revealed that in the first model PD173074 administered on its own eliminated tumors in 50% of the mice, and these mice remained disease-free for at least one year. In the second model, both PD173074 and the traditional chemotherapy agent cisplatin given separately slowed tumor growth. Yet, when the drugs were combined, they acted significantly faster than either drug individually.

At the molecular level, the investigators found that the beneficial effects of PD173074 treatment were not a consequence of its known antiangiogenic activity, but instead correlated with increased apoptosis (caspase 3 and cytokeratin 18 cleavage).

"Lung cancer is the most common cancer killer in the world and over 100 people in the UK are diagnosed with the disease every day. Around one in five of those people will have small-cell lung cancer. Although it responds to chemotherapy initially, the tumors soon become resistant to treatment and sadly nearly all people with the disease do not survive," explained senior author Dr. Michael Seckl, professor of molecular oncology at Imperial College London.

"We urgently need to develop new treatments for this disease. Our new research in mice suggests that it may be possible to develop the drug PD173074 into a new targeted therapy for small-cell lung cancer," said Dr. Seckl. "We hope to take this drug, or a similar drug that also stops FGF-2 from working, into clinical trials next year to see if it is a successful treatment for lung cancer in humans. An added bonus of this drug is that it could be taken orally, which would make it less invasive than some other forms of cancer therapy."

Related Links:
Imperial College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more